Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 3/6/2026 | $8.50 | Equal Weight → Underweight | Barclays | |
| 1/5/2026 | $12.00 | Outperform → In-line | Evercore ISI | |
| 12/17/2025 | $9.00 | Hold → Underperform | Jefferies | |
| 12/15/2025 | $13.00 | Buy → Neutral | BofA Securities | |
| 11/4/2025 | Outperform → Mkt Perform | Raymond James | ||
| 10/30/2025 | $12.00 | Overweight → Equal Weight | Barclays | |
| 10/30/2025 | $12.00 | Overweight → Neutral | Analyst | |
| 10/7/2025 | $33.00 | Buy → Neutral | Citigroup |
SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
8-K - Avantor, Inc. (0001722482) (Filer)
SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
St. Louis site strengthens integrated support for biopharma manufacturingRADNOR, Pa., April 13, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced the expansion of its North American quality control capabilities with the addition of advanced microbial and stability testing at its St. Louis manufacturing site. The investment builds on Avantor's established global quality infrastructure, expanding and localizing capabilities to better sup
RADNOR, Pa., April 3, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2026 financial results before the market opens on Wednesday, April 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl
RADNOR, Pa., April 1, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Executive Vice President and Chief Financial Officer (CFO), R. Brent Jones, will leave the Company on or before June 24, 2026. Avantor has initiated a search to identify the Company's next CFO. To ensure a smooth transition until a new CFO is appointed, Steve Eck, Senior Vice President and Chief Accounting Officer (CAO), will serve as interim CFO upon Mr
4 - Avantor, Inc. (0001722482) (Issuer)
3 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
RADNOR, Pa., April 3, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2026 financial results before the market opens on Wednesday, April 29, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl
― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025. "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagno
Revival program underway, including relaunch of VWR brand, implementation of critical manufacturing and supply chain improvements, and upgrades to e-commerce channel Fourth Quarter 2025 Net sales of $1.66 billion, decrease of 1%; organic decrease of 4%Net income of $52 million; Adjusted EBITDA of $252 millionDiluted GAAP EPS of $0.08; adjusted EPS of $0.22Operating cash flow of $153 million; free cash flow of $117 millionFull Year 2025 Net sales of $6.55 billion, decrease of 3%; organic decline of 3%Net loss of $530 million; Adjusted EBITDA of $1,069 millionDiluted GAAP loss per share of $0.78; adjusted EPS of $0.90Operating cash flow of $624 million; free cash flow of $496 millionRADNOR, Pa
Barclays downgraded Avantor from Equal Weight to Underweight and set a new price target of $8.50
Evercore ISI downgraded Avantor from Outperform to In-line and set a new price target of $12.00
Jefferies downgraded Avantor from Hold to Underperform and set a new price target of $9.00
4 - Avantor, Inc. (0001722482) (Issuer)
4/A - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors.
RADNOR, Pa., Dec. 18, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Simon Dingemans to its Board of Directors, effective January 2, 2026. Mr. Dingemans is an accomplished executive with extensive global leadership experience across healthcare, finance and strategic business transformation. He was previously the Chief Financial Officer of GlaxoSmithKline plc, a Partner at Goldman Sachs, and a Managing Dire
RADNOR, Pa., Dec. 4, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced the appointment of Sanjeev Mehra to its Board of Directors, effective immediately. Mr. Mehra is Co-Founder and serves as Managing Partner of Periphas Capital LP, a private equity firm focused on investing in technology enabled businesses in services, consumer and industrial end markets. Prior to founding Periphas, Mr. Mehra spent over 30 years at Goldman,
SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)
SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)
SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)